Related Experiment Video
Updated: Aug 7, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Integrative genomic profiling reveals characteristics of lymph node metastasis in small cell lung cancer
Kangle Kong1, Shan Hu1, Jiaqi Yue1
1Department of Thoracic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Background:
Small cell lung cancer (SCLC) is the most aggressive lung cancer subtype, with more than 70% of patients having metastatic disease and a poor prognosis. However, no integrated multi-omics analysis has been performed to explore novel differentially expressed genes (DEGs) or significantly mutated genes (SMGs) associated with lymph node metastasis (LNM) in SCLC.
Methods:
In this study, whole-exome sequencing (WES) and RNA-sequencing were performed on tumor specimens to investigate the association between genomic and transcriptome alterations and LNM in SCLC patients with (N+, n=15) or without (N0, n=11) LNM.
Results:
The results of WES revealed that the most common mutations occurred in TTN (85%) and TP53 (81%). The SMGs, including ZNF521, CDH10, ZNF429, POLE, and FAM135B, were associated with LNM. Cosmic signature analysis showed that mutation signatures 2, 4, and 7 were associated with LNM. Meanwhile, DEGs, including MAGEA4, FOXI3, RXFP2, and TRHDE, were found to be associated with LNM. Furthermore, we found that the messenger RNA (mRNA) levels of RB1 (P=0.0087), AFF3 (P=0.058), TDG (P=0.05), and ANKRD28 (P=0.042) were significantly correlated with copy number variants (CNVs), and ANKRD28 expression was consistently lower in N+ tumors than in N0 tumors. Further validation in cBioPortal revealed a significant correlation between LNM and poor prognosis in SCLC (P=0.014), although there was no significant correlation between LNM and overall survival (OS) in our cohort (P=0.75).
Conclusions:
To our knowledge, this is the first integrative genomics profiling of LNM in SCLC. Our findings are particularly important for early detection and the provision of reliable therapeutic targets.
Insights
This study reveals key genomic and transcriptome alterations linked to lymph node metastasis in small cell lung cancer (SCLC). These findings offer potential targets for early detection and treatment of aggressive SCLC.
Area of Science:
- Oncology
- Genomics
- Transcriptomics
Background:
- Small cell lung cancer (SCLC) is highly aggressive, often presenting with metastatic disease and poor prognosis.
- Limited integrated multi-omics analysis exists for SCLC, particularly concerning lymph node metastasis (LNM).
Purpose of the Study:
- To conduct an integrated multi-omics analysis of SCLC.
- To identify differentially expressed genes (DEGs) and significantly mutated genes (SMGs) associated with LNM in SCLC.
Main Methods:
- Whole-exome sequencing (WES) and RNA-sequencing were performed on SCLC tumor specimens.
- Analysis included comparison between patients with (N+) and without (N0) lymph node metastasis.
Main Results:
- Identified SMGs (e.g., ZNF521, CDH10) and DEGs (e.g., MAGEA4, FOXI3) associated with LNM.
- Found correlations between mRNA levels of RB1, AFF3, TDG, and ANKRD28 with copy number variants (CNVs).
- ANKRD28 expression was lower in N+ tumors; LNM correlated with poor prognosis in external validation.
Conclusions:
- This is the first integrative genomics profiling of LNM in SCLC.
- Findings highlight potential biomarkers for early detection and novel therapeutic targets in SCLC.
